Focus on Multiple Myeloma: Expert Insights and Strategies for Refining Patient Care

This comprehensive program gathers insight from 5 experts to improve the skills of clinicians who treat patients with multiple myeloma, featuring education across the disease spectrum enhanced by practical tools for applying new findings in the clinic. All aspects of this program are designed to complement each other, including an interactive treatment decision aid, expert-authored modules, expert commentaries, a virtual presentation, and downloadable slidesets.
Kenneth Anderson, MD
Donna Catamero, ANP-BC, OCN, CCRC
Carol Ann Huff, MD
Shaji Kumar, MD
Jacob P. Laubach, MD, MPP
Suzanne Lentzsch, MD, PhD
Sagar Lonial, MD

Interactive Decision Support Tool

Module

In this interactive, CME/CE-certified module, Shaji Kumar, MD, provides expert perspective on advances in diagnosis and initial treatment of patients with multiple myeloma.

Shaji Kumar, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: September 2, 2016 Expiration: September 1, 2017

In this interactive, CME-certified module, Sagar Lonial, MD, provides expert perspective on advances in the treatment of patients with relapsed/refractory multiple myeloma.

Sagar Lonial, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: September 20, 2016 Expiration: September 19, 2017

Carol Ann Huff, MD, presents optimal treatment strategies for patients with newly diagnosed myeloma, including diagnosis, induction therapy, maintenance therapy, and management of particularly challenging cases.

Carol Ann Huff, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.7 Nursing contact hours Released: May 3, 2017 Expiration: May 2, 2018

In this downloadable slideset, Carol Ann Huff, MD, discusses the most recent data for newly diagnosed myeloma, including diagnosis, induction therapy, maintenance therapy, and management of particularly challenging clinical scenarios.

Released: May 3, 2017

In this CME-certified module, Jacob P. Laubach, MD, MPP, discusses current therapeutic approaches for 5 challenging relapsed/refractory myeloma patient cases. The activity includes recommendations from myeloma experts and review of data supporting optimal treatment choices in this setting.

Jacob P. Laubach, MD, MPP Physicians: maximum of 1.5 AMA PRA Category 1 Credits Registered Nurses: 1.5 Nursing contact hours Released: June 16, 2017 Expiration: June 15, 2018

In this downloadable slideset, Jacob P. Laubach, MD, MPP, discusses the most current data and expert recommendations for treatment of patients with relapsed/refractory myeloma, focusing on case-based management of particularly challenging clinical scenarios.

Released: June 16, 2017

ClinicalThought

Anti-CD38 antibodies like daratumumab can cause false-positive results on blood tests in myeloma. Do you know how to mitigate this risk?

Donna Catamero, ANP-BC, OCN, CCRC Released: October 17, 2016

With many different treatment options available for patients with R/R MM, choosing the best one can be difficult. Here is how I choose treatment for elderly patients with R/R MM.

Suzanne Lentzsch, MD, PhD Released: December 13, 2016

Multiple practice-changing myeloma studies were presented at ASH this year. In this commentary, I discuss several key findings clinicians should be aware of.

Shaji Kumar, MD Released: December 27, 2016

With many recent changes in treatment options for relapsed/refractory MM, it can be hard to keep up. In this commentary, I review some of the most important new approaches for patients with relapsed/refractory MM.

Kenneth Anderson, MD Released: January 23, 2017

Lenalidomide is now the first agent approved as maintenance therapy in myeloma after ASCT, but questions remain regarding its optimal use and identification of patients who will benefit the most.

Sagar Lonial, MD Released: April 25, 2017

With multiple recent approvals, many options exist for treating patients with myeloma. However, selecting therapy for patients relapsing after exposure to multiple therapies remains a challenge.

Suzanne Lentzsch, MD, PhD Released: May 16, 2017

Interactive Virtual Presentation

In this downloadable slideset, Shaji Kumar, MD, explores current thinking, best practices, and new findings that are improving treatment of patients with multiple myeloma.

Released: August 1, 2017

Shaji Kumar, MD, explores current thinking, best practices, and new findings that are improving treatment of patients with multiple myeloma.

Shaji Kumar, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 1, 2017 Expiration: July 31, 2018
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This activity is supported by educational grants from
Amgen
Celgene Corporation
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Takeda Oncology

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?